Core Viewpoint - The company is implementing an action plan focused on "quality improvement, efficiency enhancement, and return to shareholders" to ensure sustainable development and maintain investor trust [1][2]. Group 1: Business Development - The company has established two profit centers, focusing on stable development amidst industry adjustments and structural overcapacity, demonstrating strong resilience and adaptability [1]. - Key projects such as the amide raw material optimization and the integrated production of 200,000 tons/year of dicarboxylic acid, BDO, and NMP are progressing as planned, contributing to high-quality development [1]. - The company is enhancing market presence and optimizing industry layout, leading to increased market share and influence for its main products [1]. Group 2: Shareholder Returns - The company maintains a consistent and reasonable cash dividend policy, proposing a cash dividend of 3.00 yuan per 10 shares for the 2024 annual distribution, with a payout ratio of 32.63% of net profit attributable to shareholders [2]. - The company plans to use 200 million to 300 million yuan for share repurchases to enhance shareholder value, having already repurchased 2.3 million shares for a total expenditure of 48.1 million yuan by the end of June [2]. Group 3: Investor Relations - The company emphasizes compliance and transparency in information disclosure, achieving an "A" rating for its disclosure work for ten consecutive years [3]. - Various communication channels are established to enhance investor relations, including investor meetings, online Q&A sessions, and the release of the 2024 ESG report, which has received high recognition in the capital market [3]. Group 4: Corporate Governance - The company is committed to improving its governance structure and risk management in accordance with relevant laws and regulations, having revised its articles of association and established a rapid response mechanism for public opinion [4]. - Ongoing updates to governance policies are being made to align with new legal requirements and enhance operational standards [4].

Group 1 - The board of directors of Juchen Semiconductor Co., Ltd. held its sixth meeting of the third session, where all resolutions were deemed legal and effective [1] - The meeting approved the 2025 semi-annual report, which accurately reflects the company's financial status as of June 30, 2025, and its operational results for the first half of 2025 [1][2] - The board also approved a special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with relevant regulations [2] Group 2 - The company is actively implementing the "Quality Improvement and Efficiency Enhancement" action plan for 2025, aimed at promoting high-quality development and boosting investor confidence [3] - The board approved adjustments to the grant prices of restricted stock incentive plans for 2021, 2022, and 2023, reflecting changes due to the company's profit distribution plan [4] - The board resolved to void a portion of the 2022 restricted stock incentive plan due to the departure of an incentive object before stock vesting [4][5] Group 3 - The board approved the fulfillment of vesting conditions for the fourth vesting period of the 2021 restricted stock incentive plan, allowing 67,600 shares to vest for eligible participants [6] - The board also approved the vesting of 13,000 shares for the first batch of the 2021 restricted stock incentive plan's reserved grant portion [6] - The board confirmed the vesting of 67,925 shares for the third vesting period of the 2022 restricted stock incentive plan for eligible participants [8] Group 4 - The board approved the vesting of 6,700 shares for the second batch of the 2023 restricted stock incentive plan's first vesting period for eligible participants [9]

第十届董事会第十三次会议 2025 年 8 月 21 日 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－067 华润双鹤药业股份有限公司 第十届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 一、董事会会议召开情况 公司第十届董事会第十三次会议的召开符合《公司法》和公司《章 程》的有关规定。本次会议通知和材料于 2025 年 8 月 11 日以邮件方 式向全体董事发出，会议于 2025 年 8 月 21 日以现场及通讯方式召开。 出席会议的董事应到 11 名，亲自出席会议的董事 10 名。董事长陆文 超先生因工作原因委托董事赵骞先生出席会议，并授权对本次会议通 知中所列议题代行同意的表决权。会议由半数以上董事共同推选赵骞 先生主持。公司监事列席会议。公司董事会秘书刘驹先生列席会议。 二、董事会会议审议情况 详见上海证券交易所网站 www.sse.com.cn。 《2025 年半年度报告》 《 2025 年 半 年 度 报 告 摘 要 》 详 见 上 海 证 券 交 易 所 网 ...

Core Viewpoint - The company is committed to enhancing operational efficiency and profitability while actively returning value to investors, in line with the Shanghai Stock Exchange's initiative for listed companies to improve quality and efficiency [2][8]. Action Plan Implementation - The company has implemented a profit distribution policy that emphasizes reasonable and stable returns to investors while ensuring sustainable development [2]. - A total cash dividend of RMB 12,532,241.10 (including tax) was distributed to shareholders based on 125,322,411 shares [3]. - The company initiated a share repurchase program in November 2023, with a total repurchase amount adjusted to between RMB 105 million and RMB 205 million [3]. - As of the report period, the company has repurchased 9,386,079 shares, totaling RMB 151,381,839.01 [4]. Performance Enhancement Measures - The company focuses on independent innovation and aims to replace imports in high-end scientific instruments, developing a complete production system for various products [4][5]. - The company has adopted a "Four Focuses and Two Enhancements" strategy to deepen its market presence in the new energy sector and expand into semiconductor and overseas markets [5]. - The company is advancing its product lines in laboratory analysis instruments, particularly in ion chromatography and liquid chromatography [5][6]. Governance and Risk Management - The company has restructured its governance by abolishing the supervisory board, with responsibilities transferred to the audit committee of the board [6]. - Training programs for board members and senior management have been organized to enhance compliance and operational skills [6][7]. Investor Relations and Social Responsibility - The company has conducted four shareholder meetings and engaged with 149 institutional investors to enhance transparency and investor understanding [7]. - The company published its first Environmental, Social, and Governance (ESG) report in April 2025, achieving an ESG rating upgrade to AA [7]. Future Work Plans - The company plans to continue executing the action plan, focusing on technological innovation, operational quality, governance improvement, and investor communication to enhance shareholder value [8].

Core Viewpoint - The company is actively implementing the "Quality Improvement and Efficiency Enhancement Return" action plan to enhance its investment value and protect investors' rights, with significant progress reported in various operational areas [1][7]. Action Plan Execution - The company has established a special working leadership group to oversee the action plan, ensuring a focus on quality, efficiency, and investment returns [1]. - A comprehensive approach has been adopted, involving multiple departments to drive high-quality development and enhance investment value [1]. Measures Implementation Effects Improvement of Operational Quality - The company is focusing on dual drivers of R&D innovation and external development to enhance core competitiveness, with increased R&D investment and a shift from "technology-oriented" to "value-oriented" product development [2]. - Smart factory initiatives have been launched, resulting in increased production capacity and labor productivity [2]. - The company is pursuing mergers and acquisitions in targeted segments, with three product agreements completed [2]. Accelerating New Quality Productivity - The company is advancing its innovation transformation, having completed the first phase of its R&D strategy and is now moving into deeper strategic phases [3]. - A total of 15 projects are in progress, with significant breakthroughs in innovative drug development, including the launch of a pediatric microtablet formulation and clinical approvals for several oncology drugs [3]. Enhancing Corporate Governance - The company is optimizing its governance structure and has initiated revisions to core regulations to align with new legal requirements [4]. - The board structure is being improved, with a focus on enhancing oversight and integrating sustainable development into strategic planning [4]. Strengthening Responsibility of Key Personnel - A responsibility mechanism has been implemented to align performance incentives with company results, ensuring accountability among management [5]. - The company has activated a stock incentive plan to motivate key personnel and align their interests with company performance [5]. Increasing Investor Returns - The company has established a comprehensive market value management system, with a total cash dividend and share buyback amounting to 1.4 billion yuan over the past three years, achieving a cash dividend ratio of 84% [6]. - A semi-annual dividend distribution has been initiated to enhance shareholder returns [6]. Enhancing Investor Communication - The company is expanding its investor relations communication channels, including hybrid shareholder meetings and various interactive sessions to engage with investors [6]. - Innovative information dissemination methods are being employed to improve transparency and investor understanding of company performance [6]. Conclusion - The company is committed to continuously evaluating and optimizing the "Quality Improvement and Efficiency Enhancement Return" action plan to ensure effective implementation and adapt to market changes [7].

Core Viewpoint - Zhejiang Longsheng Group Co., Ltd. held its second board meeting of the tenth session on August 21, 2025, where several key resolutions were passed, including the approval of the 2025 semi-annual report and a profit distribution plan [1][2]. Group 1: Board Meeting Details - The board meeting was convened with all 9 directors present, and it complied with relevant laws and regulations [1]. - The meeting was chaired by Chairman Ruan Weixiang [1]. Group 2: Resolutions Passed - The board approved the 2025 semi-annual report with a unanimous vote of 9 in favor [1]. - A profit distribution plan was approved, proposing a cash dividend of 2.00 yuan per 10 shares (including tax), also receiving 9 votes in favor [2]. - The "Quality Improvement and Efficiency Enhancement" action plan was approved with unanimous support [2]. - The board approved an application for the registration and issuance of short-term financing bonds, with all votes in favor [2]. - A proposal to cancel the supervisory board and amend the company's articles of association was passed unanimously [3]. - Several amendments to the company's governance rules, including the shareholder meeting rules and board meeting rules, were approved, all receiving unanimous support [4][5]. Group 3: Upcoming Actions - The board agreed to convene the first extraordinary general meeting of 2025, with the notice to be disclosed [5].

证券代码：603053 证券简称：成都燃气 公告编号：2025-025 成都燃气集团股份有限公司 成都燃气集团股份有限公司（以下简称"成都燃气"或"公司"） 第三届董事会第十四次会议（以下简称"本次会议"）于 2025 年 8 月 22 日以通讯方式召开，会议通知于 2025 年 8 月 12 日以书面、电 话、邮件等方式送达。经本次会议召集人王柄皓先生同意，本次会议 增加临时提案《关于使用自有资金进行现金管理额度的议案》，公司 于 2025 年 8 月 13 日向全体董事以书面、电话、邮件等方式送达了本 次会议的补充通知。本次会议由公司董事长王柄皓先生召集并主持， 本次会议应参会董事 13 人，实际参会董事 13 人。公司监事及高级管 理人员列席了会议。本次会议的召集、召开及提案程序符合《中华人 民共和国公司法》《成都燃气集团股份有限公司章程》和《成都燃气 集团股份有限公司董事会议事规则》等有关规定。 二、董事会会议审议情况 出席会议的董事审议并以记名方式投票表决通过了如下议案： （一）审议通过《关于 2025 年半年度总经理工作报告的议案》 董事会同意公司编制的《2025 年半年度总经理工作报告》，报 告 ...

Core Viewpoint - The company has implemented a "Quality Improvement and Efficiency Enhancement" action plan for 2025, focusing on enhancing operational efficiency, strengthening market competitiveness, and safeguarding investor interests. Group 1: Company Overview - The company is focused on the human vaccine sector, particularly influenza vaccines, and has developed a product line covering ten vaccines for five infectious diseases [4][5]. - The company has a strong commitment to maintaining high safety and efficacy standards for its products, with its quadrivalent influenza vaccine exceeding national and European pharmacopoeia standards [4]. Group 2: Financial Data - The company reported a total R&D investment of 23.85 million yuan in the first half of 2025, reflecting a year-on-year increase of 15.25% [8]. - The company has effectively managed its costs, resulting in a decrease in management expenses compared to the previous year [12]. Group 3: Operational Highlights - The company has accelerated the production and approval process for its quadrivalent influenza vaccine, aiming to increase market share by improving production efficiency [6][7]. - The company has established a marketing network covering over 2,000 disease control centers across 30 provinces, enhancing customer service and exploring new sales channels [10]. Group 4: R&D and Innovation - The company is actively pursuing R&D in various vaccine areas, including rabies, chickenpox, and pneumonia, with several projects progressing through clinical trials [8]. - The company has initiated the III phase clinical trial for its quadrivalent influenza vaccine for children, demonstrating its commitment to innovation [8]. Group 5: Governance and Compliance - The company has strengthened its governance structure, ensuring compliance with regulatory requirements and enhancing decision-making efficiency through various board committees [13][20]. - The company has conducted multiple board meetings and shareholder meetings to ensure transparency and effective governance [14][19]. Group 6: Investor Relations - The company emphasizes investor communication, planning to hold a performance briefing to address investor concerns and enhance transparency [26][27]. - The company has established a mechanism for timely responses to investor inquiries, ensuring that information is accurate and complete [18][19]. Group 7: Fund Management - The company has raised 1.21396 billion yuan through its public offering, with net proceeds of 1.13567 billion yuan after deducting issuance costs [35][36]. - As of June 30, 2025, the company had a balance of 119.05 million yuan in unutilized raised funds, demonstrating effective fund management [37]. Group 8: Future Outlook - The company plans to continue enhancing its R&D efforts and operational efficiency in the second half of 2025, aiming to strengthen its market position and investor returns [9][23].

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 除上述条款修订外，原《公司章程》其他条款的修订为非实质性修订。主要包括条款编号、援引条款序 号的相应调整、标点符号的调整、数字大小写替换以及"股东大会"统一修改为"股东会"等，因修订内容 较多且修订范围较广，不涉及权利义务变动，不进行逐条列示。 以上事项尚需提交股东大会审议，同时，公司董事会提请股东大会授权公司董事会及其授权人士办理上 述事项涉及的工商变更登记、《公司章程》备案等相关事宜，相关登记、备案最终以市场监督管理部门 核准的内容为准。修订后的《公司章程》于同日通过上海证券交易所网站（ www.sse.com.cn）予以披 露。 二、制定及修订部分内部治理制度的情况 为进一步加强公司的规范运作及内控管理水平，完善公司治理结构，根据《公司法》《章程指引》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第1号——规范运 作》等法律法规、规范性文件以及《公司章程》的最新修订的情况，并结合公司实际情况，拟制定及修 订部分治理制度，具体情况如下： ■ 上述制度的制定及修订已经公司第二届董事会第六次会议审议通过，其中《合肥颀中科技 ...

Meeting Overview - The board meeting of Xi'an Ruilian New Materials Co., Ltd. was held on August 21, 2025, with all 9 directors present, confirming compliance with relevant laws and company regulations [1][2]. Resolutions Passed - The board approved the 2025 semi-annual report and its summary, adhering to the disclosure requirements set by the China Securities Regulatory Commission and the Shanghai Stock Exchange [1][2]. - A special report on the storage and usage of raised funds for the first half of 2025 was also approved, in line with regulatory guidelines [2]. - The board passed a semi-annual evaluation report on the "Quality Improvement and Efficiency Enhancement Return" action plan for 2025, which aims to enhance company performance and governance [2][3].